Elicio Therapeutics Inc — Financial Statements (NASDAQ:ELTX) | MetaTrader

Open full chart

新闻

Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why

Elicio reports antigen spreading in 87% of evaluated cancer patients

Elicio Therapeutics appoints Marc Wolfgang as chief technology officer

Elicio reports strong immune responses in phase 2 KRAS cancer vaccine trial

Elicio’s cancer therapy shows immune response across diverse HLA types

Elicio的癌症疫苗ELI-002在99%的患者中显示强烈免疫反应

Elicio’s cancer vaccine ELI-002 shows strong immune response in 99% of patients

Elicio (ELTX) Q2 Loss Beats Estimates

H.C. Wainwright raises Elicio Therapeutics stock price target to $13 on trial outlook

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

Elicio secures $10 million to extend cash runway